Literature DB >> 8045491

Histopathological study of intrahepatic aberrant vessels in cases of noncirrhotic portal hypertension.

M Ohbu1, M Okudaira, K Watanabe, S Kaneko, T Takai.   

Abstract

Aberrant vessels, which are defined as dilated blood vessels immediately adjacent to the peripheral portal tract, appear under conditions of extrahepatic portal obstruction and nodular regenerative hyperplasia as well as idiopathic portal hypertension. Our study was undertaken to compare their morphological aspects in these three disease cases. Aberrant vessels were found in 84% of cases of idiopathic portal hypertension, 67% of cases of extrahepatic portal obstruction infantile type, 78% of cases of extrahepatic portal obstruction adult type and 83% of cases of nodular regenerative hyperplasia. They were divided into three types: type I--no communication with the portal vein, the lumen of which is normally open; type II--communication with the portal vein; and type III--no communication with the portal vein, which is occluded. The most common types of aberrant vessel were type III in idiopathic portal hypertension (51%), type I in extrahepatic portal obstruction infantile type (46%), type II in extrahepatic portal obstruction adult type (43%) and type III in nodular regenerative hyperplasia (45%). Serial sections revealed transition between types I, II and III, at frequencies between types II and III, types I and II, and types I and III of 35.7%, 33.7% and 30.6%, respectively. Aberrant vessels demonstrated the same immunoreactivity as portal veins for collagen type IV, laminin, factor VIII and ulex europaeus agglutinin-I. They were concluded to arise from the vasa septalis or inlet venules, which would be used as intrahepatic shunts draining portal blood flow blocked by stenosed portal veins. Increased portal pressure would be expected to enhance development of aberrant vessels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045491

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Masayoshi Kage
Journal:  Hepatol Int       Date:  2017-09-13       Impact factor: 6.047

Review 2.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Maria Guido; Samantha Sarcognato; Diana Sacchi; Guido Colloredo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

3.  Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension.

Authors:  Kadim Bayan; Yekta Tüzün; Serif Yilmaz; Naime Canoruc; Mehmet Dursun
Journal:  J Thromb Thrombolysis       Date:  2008-08-07       Impact factor: 2.300

4.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

5.  Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension.

Authors:  Hiroyasu Morikawa; Akihiro Tamori; Shuhei Nishiguchi; Masaru Enomoto; Daiki Habu; Norifumi Kawada; Susumu Shiomi
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

Review 6.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

7.  Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension.

Authors:  Andrea De Gottardi; Susana Seijo; Montserrat Milá; M Isabel Alvarez; Miquel Bruguera; Juan G Abraldes; Jaime Bosch; Juan-Carlos García-Pagán
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.